Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2011-1-14
pubmed:abstractText
We assessed the efficacy, tolerance and cost of a 3 mg/kg starting dose of infliximab for ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1778-7254
pubmed:author
pubmed:copyrightInfo
Copyright © 2010 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
78
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
50-5
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs.
pubmed:affiliation
Department of Pharmacy, Rouen University Hospital, 76031 Rouen cedex, France.
pubmed:publicationType
Journal Article